| Name | Alliance Pharma |
|---|---|
| Epic | APH |
| Isin | GB0031030819 |
| Index | AIM100 AIM350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 46.95p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £253.80 | Debt ratio | n/a |
| Shares in issue | 540.40 | Debt-to-equity ratio | n/a |
| P/E ratio | 12.4 | Assets / equity ratio | n/a |
| Total dividends per share | 1.776p | Price to book value | n/a |
| Dividend yield | 3.4 | ROCE | 16.17 |
| Dividend cover | 2.41 | EPS growth | -33 |
| Earning per share | 0.17 | 52-week high / low | 29.35p / 47.76p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| Final | 2023-06-22 | 2023-07-18 | 1.184p |
| Interim | 2022-12-22 | 2023-01-19 | 0.592p |
| Final | 2022-06-09 | 2022-07-07 | 1.128p |
| Interim | 2021-12-16 | 2022-01-07 | 0.563p |
| Final | 2021-06-10 | 2021-07-08 | 1.074p |
| Interim | 2020-12-17 | 2021-01-07 | 0.536p |
| Interim | 2019-12-19 | 2020-01-10 | 0.536p |
| Final | 2019-06-13 | 2019-07-11 | 0.977p |
| Interim | 2018-12-20 | 2019-01-10 | 0.487p |
| Company name | Alliance Pharma |
|---|---|
| Address | Avonbridge House, Bath Road, Chippenham, Wiltshire, United Kingdom, SN15 2BB |
| Telephone | +44 (0)1249 466966 |
| Website | http://www.alliancepharma.co.uk |
| Director | Position |
|---|---|
| Mr Peter Butterfield | CEO |
| Mr Andrew Franklin | CFO |
| Mr Camillo Pane | Chairman |
| Mr Eva-Lotta Sjöstedt | Non-Executive Director |
| Mr Richard McKenzie | Non-Executive Director |
| Mr Richard Jones | Senior Independent Director |
| Mr Kristof Neirynck | Independent Non-Executive Director |
| Mr Martin Sutherland | Independent Non-Executive Director |
| Mr Jeyan Heper | Chief Operating Officer |
| Assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Reporting date | 31/12/22 | 31/12/21 | 31/12/20 |
| Intangible asssets and goodwill | 421.63 | 413.74 | 412.87 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 431.93 | 422.47 | 431.61 |
| Inventory / work in progress | 24.29 | 21.07 | 22.92 |
| Trade and other receivables | 49.32 | 30.82 | 25.11 |
| Cash and equivalents | 31.71 | 29.06 | 28.9 |
| Other current assets and asset held for resale | 0.16 | 0.06 | 0.31 |
| Total of all assets | 537.41 | 503.49 | 508.85 |
| Liabilities £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Short term liabilities | 47.02 | 40.58 | 30.19 |
| Long term liabilities | 202.73 | 180.42 | 197.71 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 249.75 | 221 | 227.9 |
| Net assets £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Net assets | 287.66 | 282.49 | 280.96 |
| Equity £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Share capital | 5.4 | 5.38 | 5.33 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | 108.24 | 116.42 | 117.7 |
| Share premium account | 151.65 | 151.33 | 150.65 |
| Total equity | 287.66 | 282.49 | 280.96 |
| Income £ (m) | 2022 | 2021 | 2020 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | 10.57 | 21.57 | 16.32 |
| Pre-tax profit | 5.21 | 18.16 | 13.02 |